Витамин D (стероидный гормон) и заболевания нервной системы (обзор литературы)
Реферат
Представлен обзор публикаций по витамину D, его роли в развитии и патогенезе хронических заболеваний нервной системы. Предмет: зависимость развития хронических заболеваний нервной системы от уровня витамина D. Методы: поиск статей в базе данных PubMed, а также через отечественные электронные ресурсы по тегам vitamin D (витамин D), brain diseases (заболевания головного мозга), chronic nervous system diseases (хронические заболевания нервной системы), Parkinson’s disease (болезнь Паркинсона), Alzheimer’s disease (болезнь Альцгеймера), multiple sclerosis (рассеянный склероз), schizophrenia (шизофрения). Результаты. Витамин D, будучи стероидным гормоном, оказывает стимулирующее влияние на мозговую активность как у эмбриона, так и у взрослого индивида; регулирует деятельность нейронных кругов, а также двигательное и эмоциональное поведение. Низкие уровни витамина D в плазме крови обнаружены у пациентов с болезнью Паркинсона, болезнью Альцгеймера, рассеянным склерозом, шизофренией, расстройством аутистического спектра и при нарушениях сна. Обсуждение. Данные представленных современных исследований противоречивы, необходимо дальнейшее изучение значимости гиповитаминоза витамина D для манифестации хронических заболеваний нервной системы и их прогрессирования, а также эффективности препаратов витамина D у пациентов с хронической патологией нервной системы.
Тэги
1. McCollum E.F., Simmonds N., Becker J.E., Shipley P.G., Pitz W., Bunting R.W. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. Studies on experimental rickets. XXI. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. 1922. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. J. Biol. Chem. 2002. 277 (19): E8. doi: 10.1111/j.1753-4887.1975.tb07097.x
2. de Luca H.F. History of the discovery of vitamin D and its active metabolites. BoneKey Reports. 2014; 3: 479. doi: 10.1038/bonekey.2013.213
3. Авцын А.П., Жаворонков А.А., Риш М.А., Строчкова Л.С. Микроэлементозы человека: этиология, классификация, органопатология. М.: Медицина, 1984. 495 c.
Avcyn A.P., Zhavoronkov A.A., Rish M.A., Strochkova L.S. Microelementosis of human: ethiology, classification, organopathology. Moscow: Meditsina, 1984. 495 p. [In Russian].
4. Wang T.T., Tavera-Mendoza L.E., Laparriere D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H. Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005; 19: 2685–2695. doi: 10.1210/me.2005-0106
5. Sharif K., Sharif Y., Watad A., Yavne Y., Lichtbroun B., Bragazzi N.L., Amital H., Shoenfeld Y. Vitamin D, autoimmunity and recurrent pregnancy loss: more than an association. Am. J. Reprod. Immunol. 2018; 80 (3): e12991. doi: 10.1111/aji.12991
6. Ali A., Cui X., Eyles D. Developmental vitamin D deficiency and autism: putative pathogenic mechanisms. J. Steroid Biochem. Mol. Biol. 2018; 175: 108–118. doi:10.1016/j.jsbmb.2016.12
7. Eyles D., Almeras L., Benech P., Patatian A., Mackay-Sim A., McGrath J., Féron F. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J. Steroid Biochem. Mol. Biol. 2007; 103 (3–5): 538–545. doi: 10.1016/j.jsbmb.2006.12.096
8. Pertile R.A., Cui X., Eyles D.W. Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016; 333: 193–203. doi:10.1016/j.neuroscience.2016.07.020
9. Łukaszyk E., Bień-Barkowska K., Bień B. Cognitive functioning of geriatric patients: is hypovitaminosis d the next marker of cognitive dysfunction and dementia? Nutrients. 2018; 10 (8): E1104. doi: 10.3390/nu.10081104
10. Hiller A., Murchison C.F., Lobb B.M., O’Connor S., O’Connor M., Quinn J.F. A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson’s disease: does age matter? PLoS One. 2018; 13 (9): e0203637. doi: 10.1371/journal.pone.0203637
11. Pierrot-Deseilligny C., Souberbielle J.C. Vitamin D and multiple sclerosis: an update. Mult. Scler. Relat. Disord. 2017; 14: 35–45. doi: 10.1016/j.msard.2017.03.014
12. Faurschou A., Schuster S., Kiess W., Bogh M.K., Philipsen P.A., Wulf H.C. The relation between sunscreen layer thickness and vitamin D production after ultraviolet B exposure: A randomizes clinical trial. Br. J. Dermatol. 2012; 167 (2): 391–395. doi:10.1111/j.1365-2133
13. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004; 29: 664–673. doi: 10.1016/j.tibs.2004.10.005
14. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004; 29 (12): 664–673. doi: 10.1016/j.tibs.2004.10.005
15. Hewison M., Adams J.S. Extrarenal 1α-hydroxylase. In: Vitamin D. Ed. D. Feldman, J.W. Pike, J.S. Adams. San Diego: Academic Press, 2011; 777–804.
16. Gil A., Plaza-Diaz J., Mesa A.D. Vitamin D: classic and novel actions. Ann. Nutr. Metab. 2018; 72: 87–95. doi: 10.1159/000486536
17. Rochel N., Molnár F. Structural aspects of Vitamin D endocrinology. Mol. Cell. Endocrinol. 2017; 453: 22–35. doi: 10.1016/j.mce.2017.02.046
18. Shoenfeld Y., Giacomelli R., Azrielant S., Berardicurti O., Reynolds J.A., Bruce I.N. Vitamin D and systemic lupus erythematosus – The hype and the hope. Autoimmun. Rev. 2018; 17 (1): 19–23. doi: 10.1016/j.autrev.2017.11.004
19. Cui X., Gooch H., Petty A., McGrath J.J., Eyles D. Vitamin D and the brain: genomic and non-genomic actions. Mol. Cell. Endocrinol. 2017; 453: 131–143. doi: 10.1016/j.mce.2017.05.035
20. Eyles D.W., Burne T.H., McGrath J.J. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front. Neuroendocrinol. 2013; 34 (1): 47–64. doi: 10.1016/j.yfrne.2012.07.001
21. Carlberg C. Genome-wide (over) view on the actions of vitamin D. Front. Physiol. 2014; 5: 167. doi: 10.3389/fphys.2014.00167
22. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., Murad M.H., Weaver C.M., Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011; 96 (7): 1911–1930. doi: 10.1210/jc.2011-0385
23. Bivona G., Agnello L., Ciaccio M. Vitamin D and immunomodulation: is it time to change the reference value? Ann. Clin. Lab. Sci. 2017; 47 (4): 508–510.
24. Rahman A., Al-Taiar A., Shaban L., Al-Sabah R., Al-Harbi A., Mojiminiyi O. Plasma 25-hydroxy vitamin D is not associated with either cognitive function or academic performance in adolescents. Nutrients. 2018; 10 (9): E1197. doi: 10.3390/nu10091197
25. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 2006; 81 (3): 353–373. doi: 10.4065/81.3.353
26. Bichoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich Th., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006; 84 (1): 18–28. doi: 10.1093/ajcn/84.1.18
27. Евсеева Г.П., Цех О.Ю., Токарева Н.С., Учакина Р.В., Ефименко М.В., Вьюшков К.К., Белова Н.В., Целых Е.Д., Супрун С.В., Козлов В.К. Обеспеченность витамином D детей и подростков Приамурья. Здоровая семья – 21 век. 2014; 4 (3): 23–35. doi: 10.12737/20121
Evseeva G.P., Tsekh O. Yu., Tokareva N. S., Uchakina R. V., Efimenko M.V., V’yushkov K.K., Belova N.V., Tselikh E.D., Suprun S.V., Kozlov V.K. Vitamin D supply of children and teenagers in Amur river region. Zdorovaya sem’ya – 21 vek = Healthy Family – 21 century. 2014; 4 (3): 23–35. [In Russian]. doi: 10.12737/20121
28. Захарова И.Н., Боровик Т.Э., Творогова Т.М., Дмитриева Ю.А., Звонкова Н.Г. Витамин D – новый взгляд на роль в организме: учебное пособие. М.: ФГБОУ ДПО РМАПО, 2014. 104 с.
Zaharova I.N., Borovik T.E., Tvorogova T.M., Dmitrieva Yu.A., Zvonkova N.G. Vitamin D – a new view on the role in the organism: Tutorial. Moscow, 2014. 104 p. [In Russian].
29. Громова О.А., Торшин И.Ю. Витамины и минералы – между Сциллой и Харибдой. О мисконцепциях и других чудовищах. М.: МЦНМО, 2013. 693 c.
Gromova O.A., Torshin I.Yu. Vitamines and minerals – between Scilla and Haribda. About misconceptions and other beasts. Moscow, 2013. 693 p. [In Russian].
30. Lee J.M., Smith J.R., Philipp B.L., Chen T.C., Mathieu J., Holick M.F. Vitamin D deficiency in a healthy group of mothers and new born infants. Clin. Pediatr. (Phila.). 2007; 46: 42–44. doi: 10.1177/0009922806289311
31. Holick M.F. Vitamin D status: Measurement, interpretation, and clinical application. Ann. Epidemiol. 2009; 19 (2): 73–78. doi: 10.1016/j.annepidem.2007.12.001
32. Kumar J., Muntner P., Kaskel F.J., Hailpern S.M., Melamed M.L. Prevalence and associatiions of 25-hydroxyvitamin D deficiency in US children, NHANES 2001–2004. Pediatrics. 2009; 124: 362–370. doi: 10.1542/peds.2009-0051
33. Beghin L., Huybrechts I., Vicente-Rodriguez G., Henauw S.D., Gottrand F., Gonzales-Gross M., Dallongeville J., Sjostrom M., Leclercq C., Dietrich S., Castillo M., Plada M., Molnar D., Kersting M., Gilbert C.C., Moreno L.A. Main characteristics and participation rate of European adolescents included in the HELENA study. Arch. Public Health. 2012; 70 (1): 14. doi: 10.1186/0778-7367-70-14
34. Шишкова В.Н. Прием витамина D пожилыми людьми или женщинами в постменопаузе: обновление рекомендаций Европейского общества по клиническим и экономическим аспектам остеопороза и остеоартрита (ESCEO, 2013). Фарматека. 2013; 5-13: 39–42.
Shishkova V.N. Vitamin D supplement in elder people and women in postmenopause: the renewal of European society recommendations of clinical and economical aspects of osteoporosis and octeoartritis (ESCEO, 2013). Farmateka = Pharmateca. 2013; (5-13): 39–42. [In Russian].
35. Bouillon R. Vitamin D: From photosynthesis, metabolism and action to clinical applications. In: Endocrinology, 3rd Edition. Philadelphia: W.B. Saunders Co., 2001. 1009–1028. doi: 10.1038/nrendo.2017.31
36. Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006; 83: 754–759. doi: 10.1093/ajcn/83.4.754
37. Zhou C., Lu F., Cao K., Xu D., Goltzman D., Miao D. Calcium-independent and 1.25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008; 74: 170–179. doi: 10.1038/ki.2008.101
38. Bodnar L.M., Catov J.M., Roberts J.M., Simhan H.N. Pregnancy obesity predicts poor vitamin D status in mothers and their neonates. J. Nutr. 2007; 137: 2437–2442. doi: 10.1093/jn/137.11.2437
39. Xu Z., Jing X., Li G., Sun J., Guo H., Hu Y., Sun F., Wen X., Chen F., Wang T., Lu X.P. Valproate decreases vitamin D levels in pediatric patients with epilepsy. Seizure. 2019; 71: 60–65. doi: 10.1016/j.seizure.2019.06.009
40. Calza L., Borderi M., Granozzi B., Malosso P., Pancaldi L., Bon I., Re M.C. Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy. HIV Res. Clin. Pract. 2019; 20 (6): 131–139. doi: 10.1080/25787489.2020.1724749
41. Скрипникова И.А. Диагностика, лечение и профилактика дефицита витамина D. Остеопороз и остеопатии. 2012; 1: 34–37.
Skripnikova I.A. Diagnosis, treatment and prevention vitamin D deficiency. Osteoporoz i osteopatii = Osteoporosis and Bone Diseases. 2012; 1: 34–37. [In Russian].
42. Hoel D.G., Berwick M., Gruijl F.R., Holickd M.F. The risk and benefit of sun exposure. Dermatoendocrinology. 2016; 8: e1248325. doi: 10.1080/19381980.2016.1248325
43. Trinko J.R., Land B.B., Solecki B.W., Wickham R.J. Tellez L.A., Maldonado-Aviles J., de Araujo I.E., Addy N.A., DiLeone R.J. Vitamin D3: a Role in dopamine circuit regulation, diet-induced obesity, and drug consumption. eNeuro. 2016; 3 (2): ENEURO.0122–15.2016. doi: 10.1523/ENEURO.0122-15.2016
44. Lin Z., Li W. The role of vitamin D and its analogs ininflammatory diseases. Curr. Top. Med. Chem. 2016; 16 (11): 1242–1261. doi: 10.2174/1568026615666150915111557
45. Autier P., Mullie P., Macacu A., Dragomir M., Boniol M., Coppens K., Pizot C., Boniol M. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomized trials. Lancet Diabetes Endocrinol. 2017; 5 (12): 986–1004. doi: 10.1016/S2213-8587(17)30357-1
46. Mak A. The impact of vitamin D on the immunopathophisiology, disease activity, and extra-muskuloskeletal manifestations of systemic erithematosus lupus. Int. J. Mol. Sci. 2018; 19 (8): E2355. doi: 10.3390/ijms19082355
47. Moretti R., Morelli M.E., Caruso P. Vitamin D in neurological diseases: a rational for a pathogenic impact. Int. J. Mol. Sci. 2018; 19: 2245. doi: 10.3390/ijms19082245
48. Bivona G., Agnello L., Pivetti A., Milano S., Scazzone C., Lo Sasso B., Ciaccio M. Association between hypovitaminosis D and systemic sclerosis: true or fake? Clin. Chim. Acta. 2016; 458: 115–119. doi: 10.1016/j.cca.2016.04.026
49. Agnello L., Scazzone C., Lo Sasso B., Bellia C., Bivona G., Realmuto S., Brighina F., Schillaci R., Ragonese P., Salemi G., Ciaccio M. VDBP, CYP27B1 and 25-hydroxyvitamin D gene polymorphism analyses in a group of sicilian multiple sclerosis patients. Biochem. Genet. 2017; 55 (2): 183–192. doi: 10.1007/s10528-016-9783-4
50. Miller J.W., Harvey D.J., Beckett L.A., Green R., Tomaszewski Farias S., Reed B.R., Olichney J.M., Mungas D.M., DeCarli Ch. Vitamin D status and rates of cognitive decline in a multi-ethnic cohort of older adults. JAMA Neurol. 2015; 72 (11): 1295–1303. doi: 10.1001/jamaneurol.2015.2115
51. Trochoutsou A.I., Kloukina V., Samitas K., Xanthou G. Vitamin D in the immune system: genomic and non-genomic actions. Mini Rev. Med. Chem. 2015; 15 (11): 953–963. doi: 10.2174/1389557515666150519110830
52. Scazzone C., Agnello L., Ragonese P., Lo Sasso B., Bellia C., Bivona G., Schillaci R., Salemi G., Ciaccio M. Association of CYP2R1 rs10766197 with MS risk and disease progression. J. Neurosci. Res. 2018; 96 (2): 297–304. doi: 10.1002/jnr.24133
53. Bivona G., Agnello L., Scazzone C., Lo Sasso B., Bellia C., Ciaccio M. Procalcitonin and community-acquired pneumonia (CAP) in children. Clin. Chim. Acta. 2015; 451 (Pt. B): 215–218. doi: 10.1016/j.cca.2015.09.031
54. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005; 29 (1): 21–30. doi: 10.1016/j.jchemneu.2004.08.006
55. De Abreu F.D.A., Eyles D., Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009; 34 (1): 265–277. doi: 10.1016/j.psyneuen.2009.05.023
56. Stumpf W.E., Sar M., Clark S.A., DeLuca H.F. Brain target sites for 1,25-dihydroxyvitamin D3. Science. 1982; 215 (4538): 1403–1405. doi: 10.1126/science.6977846
57. Almeras L., Eyles D., Benech P., Laffite D., Villard C., Patatian A., Boucraut J., Mackay-Sim A., McGrath J., Féron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics. 2007; 7 (5): 769–780. doi: 10.1002/pmic.200600392
58. Grecksch G., Rüthrich H., Höllt V., Becker A. Transient prenatal vitamin D deficiency is associated with changes of synaptic plasticity in the dentate gyrus in adult rats. Psychoneuroendocrinology. 2009; 34 (1): 258–264. doi: 10.1016/j.psyneuen.2009.07.004
59. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D3 and brain development. Neuroscience. 2003; 118 (3): 641–653. doi: 10.1016/s0306-4522(03)00040-x
60. Groves N.J., McGrath J.J., Burne T.H. Vitamin D as a neurosteroid affecting the developing and adult brain. Annu. Rev. Nutr. 2014; 34: 117–141. doi: 10.1146/annurev-nutr-071813-105557
61. Gezen-Ak D., Dursun E., Yilmazer S. The effect of vitamin D treatment on nerve growth factor (NGF) release from hippocampal neurons. Arch. Neuropsychiatry. 2014; 51: 157–162. doi: 10.4274/npa.y7076
62. Pertile R.A.N., Cui X., Hammond L., Eyles D.W. Vitamin D regulation of GDNF/Ret signaling in dopaminergic neurons. FASEB J. 2018; 32 (2): 819–828. doi: 10.1096/fj.201700713R
63. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J. Neurosci. 2001; 21 (1): 98–108. doi: 10.1523/JNEUROSCI.21-01-00098.2001
64. Garcion E., Sindji L., Montero-Menei C., Andre C., Brachet P., Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia. 1998; 22 (3): 282–294.
65. Garcion E., Sindji L., Leblondel G., Brachet P., Darcy F. 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999; 73 (2): 859–866. doi: 10.1046/j.1471-4159.1999.0730859.x
66. Kiraly S.J., Kiraly M.A., Hawe R.D., Makhani N. Vitamin D as a neuroactive substance: Review. Sci. World J. 2006; 6: 125–139. doi: 10.1100/tsw.2006.25
67. Zhang P., Rhodes J.S., Jr G.T., Perez S.D., Southey B.R., Rodriguez-Zas S.L. Brain region-dependent gene networks associated with selective breeding for increased voluntary wheel-running behavior. PLoS One. 2018; 13 (8): e0201773. doi: 10.1371/journal.pone.0201773
68. Stein M.S., Scherer S.C., Ladd K.S., Harrison L.C. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. J. Alzheimers Dis. 2011; 26 (3): 477–484. doi: 10.3233/JAD-2011-110149
69. Burne T.H., Johnston A.N., McGrath J.J., Mackay-Sim A. Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice. Brain Res. Bull. 2006; 69 (1): 74–78. doi: 10.1016/j.brainresbull.2005.10.014
70. Okereke O.I., Singh A. The role of vitamin D in the prevention of late-life depression. J. Affect. Disord. 2016; 198: 1–14. doi: 10.1016/j.jad.2016.03.022
71. Bertone-Johnson E.R., Powers S.I., Spangler L., Larson J., Michael Y.L., Millen A.E., Bueche M.N., Salmoirago-Blotcher E., Wassertheil-Smoller S., Brunner R.L., Ockene J.K., Liu S., Manson J.E. Vitamin D supplementation and depression in the women’s health initiative calcium and vitamin D trial. Am. J. Epidemiol. 2012; 176 (1): 1–13. doi: 10.1093/aje/kwr482
72. Luo X., Ou R., Dutta R., Tian Y., Xiong H., Shang H. Association between serum vitamin D levels and Parkinson’s Disease: a systematic review and meta-analysis. Front. Neurol. 2018; 9: 909. doi: 10.3389/fneur.2018.09
73. Luong V.Q.K., Nguyên T.H.L. Vitamin D and Parkinson’s disease. J. Neurosci. Res. 2012; 90 (12): 2227–2236. doi: 10.1002/jnr.23115
74. Bertone-Johnson E.R. Vitamin D and the occurrence of depression: causal association or circumstantial evidence? Nutr. Rev. 2009; 67 (8): 481–492. doi: 10.1111/j.1753-4887.2009.2.x
75. Laughlin G.A., Kritz-Silverstein D., Bergstrom J., Reas E.T., Jassal S.K., Barrett-Connor E., McEvoy L.K. Vitamin D insufficiency and cognitive function trajectories in older adults: the rancho bernardo study. J. Alzheimers Dis. 2017; 58 (3): 871–883. doi: 10.3233/JAD-161295
76. Buell J.S., Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing «D» ecline? Mol. Aspects Med. 2008; 29 (6): 415–422. doi: 10.1016/j.mam.2008.05.001
77. Máčová L., Bičíková M., Ostatníková D., Hill M., Stárka L. Vitamin D neurosteroid and autism. Physiol. Res. 2017; 66 (3): 333–340. doi: 10.33549/physiolres.933721
78. Penckofer S., Byrn M., Adams W., Emanuele M.A., Mumby P.1, Kouba J., Wallis D.E. Vitamin D supplementation improves mood in women with type 2 diabetes. J. Diabetes Res. 2017; 2017: 8232863. doi: 10.1155/2017/8232863
79. Patrick R.P., Ames B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulse behavior. FASEB J. 2015; 29 (6): 2207–2222. doi: 10.1096/fj.14-268342
80. Al-Amin M., Bradford D., Sullivan R.K.P., Kurniawan N.D., Moon Y., Han S.-H., Zalesky A., Burne T.H.J. Vitamin D deficiency is associated with reduced hippocampal volume and disrupted structural connectivity in patients with mild cognitive impairment. Hum. Brain Mapp. 2019; 40 (2): 394–406. doi: 10.1002/hbm.24380
81. Sakuma M., Kitamura K., Endo N., Ikeuchi ., Yokoseki A., Onodera O., Oinuma T., Sato K., Nakamura K., Narita I. Low serum 25-hydroxyvitamin D increases cognitive impairment in elderly people. J. Bone Miner. Metab. 2019; 37 (2): 368–375. doi:10.1007/s00774-018-0934-z
82. Wang X., Zhang S., Lin F., Chu W., Yue Sh. Elevated Galectin-3 levels in the serum of patients with Alzheimer’s Disease. Am. J. Alzheimers Dis. Other. Demen. 2015; 30 (8): 729–732. doi: 10.1177/1533317513495107
83. Gao Q., Fan Y., Mu L.Y., Ma L., Song Z.-Q., Zhang Y.-N. S100B and ADMA in cerebral small vessel disease and cognitive dysfunction. J. Neurol. Sci. 2015; 354 (1–2): 27–32. doi: 10.1016/j.jns.2015.04.031
84. Guo L.H., Alexopoulos P., Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 2013; 263 (7): 553–560. doi: 10.1007/s00406-013-0405-4
85. Agnello L., Bivona G., Lo Sasso B., Scazzone C., Bazan V., Bellia C., Ciaccio M. Galectin-3 in acute coronary syndrome. Clin. Biochem. 2017; 0 (13-14): 797–803. doi: 10.1016/j.clinbiochem.2017.04.018
86. Zinellu A., Sotgia S., Porcu P., Casu M.A., Bivona G., Chessa R., Deiana L., Carru C. Carotid restenosis is associated with plasma ADMA concentrations in carotid endarterectomy patients. Clin. Chem. Lab. Med. 2011; 49 (5): 897–901. doi: 10.1515/CCLM.2011.121
87. Agnello L., Bivona G., Novo G., Scazzone C., Muratore R., Levantino P., Bellia C., Lo Sasso B., Ciaccio M. Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study. Scand. J. Clin. Lab. Invest. 2017; 77 (6): 428–432. doi: 10.1080/00365513.2017.1335880
88. Patel P., Shah J. Role of Vitamin D in amyloid clearance via LRP-1 upregulation in Alzheimer’s disease: a potential therapeutic target? J. Chem. Neuroanat. 2017; 85: 36–42. doi: 10.1016/j.jchemneu.2017.06.007
89. Littlejohns T.J., Henley W.E., Lang I.A., Annweiler C., Beauchet O., Chaves P.H., Fried L., Kestenbaum B.R., Kuller L.H., Langa K.M., Lopez O.L., Kos K., Soni M., Llewellyn D.J. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014; 83 (10): 920–928. doi: 10.1212/WNL.0000000000000755
90. Afzal S., Bojesen S.E., Nordestgaard B.G. Reduced 25-hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimers Dement. 2014; 10 (3): 296–302. doi: 10.1016/j.jalz.2013.05.1765
91. Buell J.S., Dawson-Hughes B., Scott T.M., Weiner D.E., Dallal G.E., Qui W.Q., Bergethon P., Rosenberg I.H., Folstein M.F., Patz S., Bhadelia R.A., Tucker K.L. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010; 74 (1): 18–26. doi: 10.1212/WNL.0b013e3181beecb7
92. Annweiler C., Llewellyn D.J., Beauchet O. Low serum vitamin D concentrations in Alzheimer’s disease: a systematic review and meta-analysis. J. Alzheimers Dis. 2013; 33 (3): 659–674. doi: 10.3233/JAD-2012-121432
93. Feart C., Helmer C., Merle B., Herrmann F.R., Annweiler C., Dartigues J.F., Delcourt C., Samieri C. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer’s disease in older adults. Alzheimers Dement. 2017; 13 (11):1207–1216. doi: 10.1016/j.jalz.2017.03.003
94. Licher S., de Bruijn R., Wolters F.J., Zillikens M.C., Ikram M.A., Ikram M.K. Vitamin D and the risk of dementia: the Rotterdam study. J. Alzheimer Dis. 2017; 60 (3): 989–997. doi: 10.3233/JAD-170407
95. Olsson E., Byberg L., Karlström B., Cederholm T., Melhus H., Sjögren P., Kilander L. Vitamin D is not associated with incident dementia or cognitive impairment: an 18-y follow-up study in community-living old men. Am. J. Clin. Nutr. 2017; 105 (4): 936–943. doi: 10.3945/ajcn.116.141531
96. Karakis I., Pase M.P., Beiser A., Booth S.L., Jacques P.F., Rogers G., DeCarli C., Vasan R.S., Wang T.J., Himali J.J., Annweiler C., Seshadri S. Association of serum Vitamin D with the risk of incident dementia and subclinical indices of brain aging: the Framingham heart study. J. Alzheimer Dis. 2016; 51 (2): 451–461. doi: 10.3233/JAD-150991
97. Przybelski R., Agrawal S., Krueger D., Engelke J.A., Walbrun F., Binkley N. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int. 2008; 19 (11): 1621–1628. doi: 10.1007/s00198-008-0619-x
98. Rossom R.C., Espeland M.A., Manson J.E., Dysken M.W., Johnson K.C., Lane D.S., LeBlanc E.S., Lederle F.A., Masaki K.H., Margolis K.L. Calcium and vitamin D supplementation and cognitive impairment in the women’s health initiative. J. Am. Geriatr. Soc. 2012; 60 (12): 2197–2205. doi: 10.1111/jgs.12032
99. Moran C., Palumbo A., Bramham J., Moran A., Rooney B., de Vito G., Egan B. Effects of a six-month multi-ingredient nutrition nupplement intervention of omega-3 polyunsaturated fatty acids, vitamin D, resveratrol, and whey protein on cognitive function in older adults: a randomised, double-blind, controlled trial. J. Prev. Alzheimers Dis. 2018; 5 (3): 175–183. doi: 10.14283/jpad.2018.11
100. Munoz-Fernandez S.S., Ivanauskas T., Lima Ribeiero S.M. Nutritional strategies in the management of Alzheimer Disease: systematic review with network meta-analysis. J. Am. Med. Dir. Assoc. 2017; 18 (10): 897 e13–897.e30. doi: 10.1016/j.jamda.2017.06.015
101. Annweiler C., Hermann F.R., Fantino B., Brugg B., Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn. Behav Neurol. 2012; 25 (3): 121–127. doi: 10.1097/WNN.0b013e31826df647
102. Bonnet A.M., Houeto J.L. Pathophysiology of Parkinson’s disease. Biomed. Pharmacother. 1999; 53 (3):117–121. doi: 10.1016/S0753-3322(99)80076-6
103. Marsili L., Rizzo G., Colosimo C. Diagnostic criteria for Parkinson’s disease: from James Parkinson to the concept of prodromal disease. Front. Neurol. 2018; 9: 156. doi: 10.3389/fneur.2018.00156 doi: 10.3389/fneur.2018.00156
104. Annweiler C., Schott A.M., Berrut G., Chauviré V., Le Gall D., Inzitari M., Beauchet O. Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010; 62 (3): 139–150. doi: 10.1159/000318570
105. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 2008; 65 (10): 1348–1352. doi: 10.1001/archneur.65.10.1348
106. Sato Y., Kikuyama M., Ozumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson disease. Neurology. 1997; 49 (5): 1273–1278. doi: 10.1212/wnl.49.5.1273
107. Knekt P., Kilkkinen A., Rissanen H., Marniemi J., Sääksjärvi K., Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch. Neurol. 2010; 67 (7): 808–811. doi: 10.1001/archneurol.2010.120
108. Ding H., Dhima K., Lockhart K.C., Locascio J.J., Hoesing A.N., Duong K., Trisini-Lipsanopoulos A., Hayes M.T., Sohur U.S., Wills A.M., Mollenhauer B., Flaherty A.W., Hung A.Y., Mejia N., Khurana V., Gomperts S.N., Selkoe D.J., Schwarzschild M.A., Schlossmacher M.G., Hyman B.T., Sudarsky L.R., Growdon J.H., Scherzer C.R. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard biomarker study. Neurology. 2013. 81 (17): 1531–1537. doi: 10.1212/WNL.0b013e3182a95818
109. Orme R.P., Bhangal M.S., Fricker R.A. Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. PLoS One. 2013; 8940: e62040. doi: 10.1371/journal.pone.0062040
110. Cass W.A., Smith M.P., Peters L.E. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann. NY Acad. Sci. 2014; 1074: 261–271. doi: 10.1196/annals.1369.023
111. Orme R.P., Middleditch C., Waite L., Fricker R.A. The role of vitamin D3 in the development and neuroprotection of midbrain dopamine neurons. Vitam. Horm. 2016; 100: 273–297. doi: 10.1016/bs.vh.2015.10.007
112. Suzuki M., Yoshioka M., Hashimoto M., Murakami M., Noya M., Takahashi D., Urashima M. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am. J. Clin. Nutr. 2013; 97 (5): 1004–1013. doi: 10.3945/ajcn.112.051664
113. Cui X., Pelekanos M., Liu P.Y., Burne T.H., McGrath J.J., Eyles D.W. The Vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience. 2013; 236: 77–87. doi: 10.1016/j.neuroscience.2013.01.035
114. Pugliatti M., Harbo H.F., Holmøy T., Kampman M.T., Myhr K.M., Riise T., Wolfson C. Environmental risk factors in multiple sclerosis. Acta Neurol. Scand. Suppl. 2008; 188: 34–40. doi: 10.1111/j.1600-0404.2008.01029.x
115. Mazdeh M., Seifirad S., Kazemi N., Seifrabie M.A., Dehghan A., Abbasi H. Comparison of vitamin D3 serum levels in new diagnosed patients with multiple sclerosis versus their healthy relatives. Acta Med. Iran. 2013; 51 (5): 289–292.
116. Ascherio A., Munger K.L. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin. Neurol. 2016; 36 (2): 103–114. doi: 10.1055/s-0036-1579693
117. Simpson S.Jr., Taylor B., Blizard L., Ponsonby A.L., Pittas F., Tremlett H., Dwyer T., Gies P., van der Mei I. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 2010; 68 (2): 193–203. doi: 10.1002/ana.22043
118. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006; 296 (23): 2832–2838. doi: 10.1001/jama.296.23.2832
119. Cortese M., Riise T., Bjørnevik K., Holmøy T., Kampman M.T., Magalhaes S., Pugliatti M., Wolfson C., Myhr K.M. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: the EnvIMS study. Mult. Scler. 2015; 21 (14): 1856–1864. doi: 10.1177/1352458515578770
120. Pozuelo-Moyano B., Benito-León J., Mitchell A.J., Hernández-Gallego J. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology. 2013; 40 (3): 147–153. doi: 10.1159/000345122
121. The International Multiple Sclerosis Genetics Consortium, The Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476 (7359): 214–219. doi: 10.1038/nature10251
122. Jia F., Shan L., Wang B., Li H., Miao C., Xu Z., Lin C.P., Saad K. Bench to bedside review: possible role of vitamin D in autism spectrum disorder. Psychiatry Res. 2018; 260: 360–365. doi: 10.1016/j.psychres.2017.12.005
123. Meguid N.A., Hashish A.F., Anwar M., Sidhom G. Reduced serum levels of 25-hydroxy and 1,25-dihydroxy vitamin D in Egyptian children with autism. J. Altern. Complement Med. 2010; 16 (6): 641–645. doi: 10.1089/acm.2009.0349
124. Mostafa G.A., Al-Ayadhi L.Y. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J. Neuroinflammation. 2012; 9: 201. doi: 10.1186/1742-2094-9-201
125. Neumeyer A.M., Gates A., Ferrone C., Lee H., Misra M. Bone density in peripubertal boys with autism spectrum disorders. J. Autism Dev. Disord. 2013; 43 (7): 1623–1629. doi: 10.1007/s10803-012-1709-3
126. Gong Z.L., Luo C.M., Wang L., Shen L., Wei F., Tong R.J., Liu Y. Serum 25-hydroxyvitamin D levels in Chinese children with autism spectrum disorders. Neuroreport. 2014; 25 (1): 23–27. doi: 10.1097/WNR.0000000000000034
127. Bener A., Khattab A.O., Al-Dabbagh M.M. Is high prevalence of Vitamin D deficiency evidence for autism disorder? In a highly endogamous population. J. Pediatr. Neurosci. 2014; 9 (3): 227–233. doi: 10.4103/1817-1745.147574
128. Du L., Shan L., Wang B., Feng J.Y., Xu Z.D., Jia F.Y. Serum levels of 25-hydroxyvitamin D in children with autism spectrum disorders. Zhongguo Dang Dai Er Ke Za Zhi. 2015; 17 (1): 68–71. doi: 10.1186/s13052-018-0587-5
129. Fernell E., Barnevik-Olsson M., Bågenholm G., Gillberg C., Gustafsson S., Sääf M. Serum levels of 25-hydroxyvitamin D in mothers of Swedish and of Somali origin who have children with and without autism. Acta Paediatr. 2010; 99 (5): 743–747. doi: 10.1111/j.1651-2227.2010.01755.x
130. Adams J.B., Audhya T., McDonough-Means S., Rubin A.R., Quig D., Geis E., Gehn E., Loresto M., Mitchel J., Atwood S., Barnhouse S., Lee W. Nutritional and metabolic status of children with autism vs neurotypical children, and the association with autism severity. Nutr. Metab. (Lond.). 2011; 8 (1): 34. doi: 10.1186/1743-7075-8-34
131. Ugur C., Gurkan C.K. Serum vitamin D and folate levels in children with autism spectrum disorders. Autism Spectr. Disord. 2014; 8 (12): 1641–1647. doi: 10.1016/j.rasd.2014.09.002
132. Wang T., Shan L., Du L., Feng J., Xu Z., Staal W.G., Jia F. Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis. Eur. Child Adolesc. Psychiatry. 2016; 25 (4): 341–350. doi: 10.1007/s00787-015-0786-1
133. Saad K., Abdel-Rahman A.A., Elserogy Y.M., Al-Atram A.A., El-Houfey A.A., Othman H.A., Bjørklund G., Jia F., Urbina M.A., Abo-Elela M.G.M., Ahmad F.A., Abd El-Baseer K.A., Ahmed A.E., Abdel-Salam A.M. Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder. J. Child Psychol. Psychiatry. 2018; 59 (1): 20–29. doi: 10.1111/jcpp.12652
134. Kokovska E., Fernell E., Billstedt E., Minnis H., Gillberg C. Vitamin D and autism: clinical review. Res. Dev. Disabil. 2012; 33 (5): 1541–1550. doi: 10.1016/j.ridd.2012.02.015
135. Patrick R.P., Ames B.N. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 2014; 28 (6): 2398–2413. doi: 10.1096/fj.13-246546
136. Gominak S.C., Stumpf W.S. The world epidemic of sleep disorders is linked to vitamin D deficiency. Med. Hypotheses. 2012; 79 (2): 132–135. doi: 10.1016/j.mehy.2012.03.031
137. Andersen M.L., Tufik S. Vitamin D as an underlying factor in sleep-related issues. J. Clin. Sleep Med. 2012; 8 (6): 699. doi: 10.5664/jcsm.2268
138. Mccarty D.E., Reddy A., Keigley Q., Kim P.Y., Marino A.A. Vitamin D, race, and excessive daytime sleepiness. J. Clin. Sleep Med. 2012; 8: 693–697. doi: 10.5664/jcsm.2266
139. Shahi M.M., Hosseini S.A., Helli B., Haghighyzade M.H., Abolfathi M. The effect of vitamin D supplement on quality of sleep in adult people with sleep disorders. Tehran Univ. Med. J. 2017; 75: 443–448.
140. Huang W., Shah S., Long Q., Crankshaw A.K., Tangpricha V. Improvement of pain, sleep, and quality of life in chronic pain patients with vitamin d supplementation. Clin. J. Pain. 2013; 29: 341–347. doi: 10.1097/AJP.0b013e318255655d
141. Gao Q., Kou T., Zhuang B., Ren Y., Dong X., Wang Q. Association between Vitamin D deficiency and sleep disorders: a systematic review and meta-analysis. Nutrients. 2018; 10 (10): E1395. doi: 10.3390/nu10101395
142. Eyles D., Trzaskowski M., Vinkhuyzen A., Mattheisen M., Meier S., Gooch H., Anggono V., Cui X., Tan M.C., Burne T.H.J., Jang S.E., Kvaskoff D., Hougaard D.M., Nørgaard-Pedersen B., Cohen A., Agerbo E., Pedersen C.B., Børglum A.D., Mors O., Sah P., Wray N.R., Mortensen P.B., McGrath J.J. The association between neonatal vitamin D status and risk of schizophrenia. Sci. Rep. 2018; 8 (1): 17692. doi: 10.1038/s41598-018-35418-z
143. Graham K.A., Keefe R.S., Lieberman J.A., Calikoglu A.S., Lansing K.M., Perkins D.O. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Interv. Psychiatry. 2015; 9 (5): 397–405. doi: 10.1111/eip.12122
144. Valipour G., Saneei P., Esmaillzadeh A. Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies. J. Clin. Endocrinol. Metab. 2014; 99 (10): 3863–3872. doi: 10.1210/jc.2014-1887
Новотный Д.А., e-mail: hellpost@yandex.ru
